(Q82239784)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and dose (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

C E M Hollak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A C Vedder

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

B Winchester

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

F Breunig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

7 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

239-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Clinical benefit of enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Fabry disease: overall effects of agalsidase alfa treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.08.006

10.1016/J.YMGME.2008.08.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18842432%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference